Apoptosis induction by Bcl-2 proteins independent of the BH3 domain

Biochemical Pharmacology

Volumn 76, Issue 11, 2008, Pages 1612-1619

  Hossini, Amir M ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Bcl 2 proteins; Bcl x; BH3; BH4

Indexed keywords

BH3 PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN DERIVATIVE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN INDUCTION; PROTEIN STRUCTURE;

APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 55949092244     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.08.013     Document Type: Article

References (84)

1. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 4 (1972) 239-257
2. Eberle J., Fecker L.F., Forschner T., Ulrich C., Rowert-Huber J., and Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 156 (2007) 18-24
3. Roos W.P., and Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 12 9 (2006) 440-450
4. Schafer Z.T., and Kornbluth S. The apoptosome: physiological, developmental, and pathological modes of regulation. Dev Cell 10 5 (2006) 549-561
5. Peter M.E., and Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10 1 (2003) 26-35
6. Russell J.H., and Ley T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20 (2002) 323-370
7. Codogno P., and Meijer A.J. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12 (2005) 1509-1518
8. Fischer U., and Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 57 2 (2005) 187-215
9. Reed J.C., and Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 106 2 (2005) 408-418
10. Chipuk J.E., and Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol 18 4 (2008) 157-164
11. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9 1 (2008) 47-59
12. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 17 (2005) 2899-2908
13. Er E., Oliver L., Cartron P.F., Juin P., Manon S., and Vallette F.M. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta-Bioenerg 1757 9-10 (2006) 1301-1311
14. Shiozaki E.N., and Shi Y.G. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 29 9 (2004) 486-494
15. Walle L.V., Lamkanfi M., and Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 15 3 (2008) 453-460
16. Lorenzo H.K., and Susin S.A. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updates 10 6 (2007) 235-255
17. Saikumar P., Mikhailova M., and Pandeswara S.L. Regulation of caspase-9 activity by differential binding to the apoptosome complex. Front Biosci 12 (2007) 3343-3354
18. Degterev A., Boyce M., and Yuan J. A decade of caspases. Oncogene 22 53 (2003) 8543-8567
19. Los M., Stroh C., Janicke R.U., Engels I.H., and Schulze-Osthoff K. Caspases: more than just killers?. Trends Immunol 22 1 (2001) 31-34
20. Fischer U., Janicke R.U., and Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10 1 (2003) 76-100
21. Daniel P.T., Schulze-Osthoff K., Belka C., and Guner D. Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 39 (2003) 73-88
22. Raisova M., Hossini A.M., Eberle J., Riebeling C., Wieder T., Sturm I., et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117 2 (2001) 333-340
23. Adams J.M. Ways of dying: multiple pathways to apoptosis. Genes Dev 17 20 (2003) 2481-2495
24. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 1 (2002) 19-30
25. Zamzami N., and Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2 1 (2001) 67-71
26. Martinou J.C., and Green D.R. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2 1 (2001) 63-67
27. Antignani A., and Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr Opin Cell Biol 18 6 (2006) 685-689
28. Tsujimoto Y., Yunis J., Onoratoshowe L., Erikson J., Nowell P.C., and Croce C.M. Molecular-cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the T(11-14) chromosome-translocation. Science 224 4656 (1984) 1403-1406
29. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in-vivo with a conserved homolog, Bax, that accelerates programmed cell-death. Cell 74 4 (1993) 609-619
30. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 9 (2007) 1324-1337
31. Collins N.L., Reginato M.J., Paulus J.K., Sgroi D.C., LaBaer J., and Brugge J.S. G(1)/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25 12 (2005) 5282-5291
32. Mathai J.P., Germain M., Marcellus R.C., and Shore G.C. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 21 16 (2002) 2534-2544
33. Willis S.N., and Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17 6 (2005) 617-625
34. Adams J.M., and Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19 5 (2007) 488-496
35. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 3 (2005) 393-403
36. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17 4 (2005) 525-535
37. Danial N.N. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13 24 (2007) 7254-7263
38. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 5813 (2007) 856-859
39. Saeki K., Yuo A., Okuma E., Yazaki Y., Susin S.A., Kroemer G., et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 7 12 (2000) 1263-1269
40. Terrones O., Etxebarria A., Landajuela A., Landeta O., Antonsson B., and Basanez G. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes. J Biol Chem 283 12 (2008) 7790-7803
41. Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J., Elangovan B., et al. A conserved domain in Bak, distinct from Bh1 and Bh2, mediates cell-death and protein-binding functions. EMBO J 14 22 (1995) 5589-5596
42. Boyd J.M., Gallo G.J., Elangovan B., Houghton A.B., Malstrom S., Avery B.J., et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11 9 (1995) 1921-1928
43. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80 2 (1995) 285-291
44. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10 5 (2006) 389-399
45. Zhang L., Ming L., and Yu H. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updates 10 6 (2007) 207-217
46. Eberle J., Kurbanov B.M., Hossini A.M., Trefter U., and Fecker L.F. Overcoming apoptosis deficiency of melanoma - hope for new therapeutic approaches. Drug Resist Updates 10 6 (2007) 218-234
47. Mund T., Gewies A., Schoenfeld N., Bauer M.K., and Grimm S. Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum. FASEB J 17 6 (2003) 696-698
48. Inohara N., Ding L., Chen S., and Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16 7 (1997) 1686-1694
49. Basanez G., Zhang J., Chau B.N., Maksaev G.I., Frolov V.A., Brandt T.A., et al. Pro-apoptotic cleavage products of Bcl-xL form cytochrome c-conducting pores in pure lipid membranes. J Biol Chem 276 33 (2001) 31083-31091
50. Kirsch D.G., Doseff A., Chau B.N., Lim D.S., de Souza-Pinto N.C., Hansford R., et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274 30 (1999) 21155-21161
51. Huang D.C., Adams J.M., and Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 17 4 (1998) 1029-1039
52. Shimizu S., Konishi A., Kodama T., and Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA 97 7 (2000) 3100-3105
53. Hotchkiss R.S., McConnell K.W., Bullok K., Davis C.G., Chang K.C., Schwulst S.J., et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 176 9 (2006) 5471-5477
54. Cantara S., Thorpe P.E., Ziche M., and Donnini S. TAT-BH4 counteracts Abeta toxicity on capillary endothelium. FEBS Lett 581 4 (2007) 702-706
55. Sugioka R., Shimizu S., Funatsu T., Tamagawa H., Sawa Y., Kawakami T., et al. BH4-domain peptide from Bcl-x(L) exerts anti-apoptotic activity in vivo. Oncogene 22 52 (2003) 8432-8440
56. Warr M.R., and Shore G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 8 2 (2008) 138-147
57. Clohessy J.G., Zhuang J.G., de Boer J., Gil-Gomez G., and Brady H.J.M. Mcl-1 interacts with truncated bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 281 9 (2006) 5750-5759
58. Zhai D.Y., Jin C.F., Huang Z.W., Satterthwait A.C., and Reed J.C. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 283 15 (2008) 9580-9586
59. Simmons M.J., Fan G., Zong W.X., Degenhardt K., White E., and Gelinas C. Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 27 10 (2008) 1421-1428
60. Yakovlev A.G., Di Giovanni S., Wang G.P., Liu W.F., Stoica B., and Faden A.I. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 279 27 (2004) 28367-28374
61. Hsu S.Y., Kaipia A., Mcgee E., Lomeli M., and Hsueh A.J.W. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 94 23 (1997) 12401-12406
62. Inohara N., Ekhterae D., Garcia I., Carrio R., Merino J., Merry A., et al. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J Biol Chem 273 15 (1998) 8705-8710
63. Boyd J.M., Malstrom S., Subramanian T., Venkatesh L.K., Schaeper U., Elangovan B., et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 79 2 (1994) 341-351
64. Vande Velde C., Cizeau J., Dubik D., Alimonti J., Brown T., Israels S., et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20 15 (2000) 5454-5468
65. Ray R., Chen G., Vande V.C., Cizeau J., Park J.H., Reed J.C., et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 275 2 (2000) 1439-1448
66. Chen G., Cizeau J., Vande V.C., Park J.H., Bozek G., Bolton J., et al. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem 274 1 (1999) 7-10
67. Kim J.Y., Cho J.J., Ha J., and Park J.H. The carboxy terminal C-tail of BNip3 is crucial in induction of mitochondrial permeability transition in isolated mitochondria. Arch Biochem Biophys 398 2 (2002) 147-152
68. Semenza G.L. Mitochondrial autophagy: life and breath of the cell. Autophagy 4 4 (2008) 534-536
69. Kataoka T., Holler N., Micheau O., Martinon F., Tinel A., Hofmann K., et al. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem 276 22 (2001) 19548-19554
70. Guo B., Godzik A., and Reed J.C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 276 4 (2001) 2780-2785
71. Coultas L., Pellegrini M., Visvader J.E., Lindeman G.J., Chen L., Adams J.M., et al. Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death Differ 10 2 (2003) 185-192
72. Ewings K.E., Wiggins C.M., and Cook S.J. Bim and the pro-survival bcl-2 proteins - opposites attract, ERK repels. Cell Cycle 6 18 (2007) 2236-2240
73. Akgul C., Moulding D.A., and Edwards S.W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 61 17 (2004) 2189-2199
74. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 4 (1993) 597-608
75. Schmitt E., Paquet C., Beauchemin M., and Bertrand R. Bcl-xES, a BH4- and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activation. Oncogene 23 22 (2004) 3915-3931
76. Hossini A.M., Geilen C.C., Fecker L.F., Daniel P.T., and Eberle J. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 25 15 (2006) 2160-2169
77. Yin X.M., Oltvai Z.N., and Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369 6478 (1994) 321-323
78. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., et al. Structure of Bcl-x(L)-Bak peptide complex: recognition between regulators of apoptosis. Science 275 5302 (1997) 983-986
79. Mitra R.S., Benedict M.A., Qian D., Foreman K.E., Ekhterae D., Nickoloff B.J., et al. Killing of sarcoma cells by proapoptotic Bcl-X(S): role of the BH3 domain and regulation by Bcl-X(L). Neoplasia 3 5 (2001) 437-445
80. Hossini A.M., Eberle R., Fecker L.F., Orfanos C.E., and Geilen C.C. Conditional expression of exogenous Bcl-X-s triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett 553 3 (2003) 250-256
81. Schendel S.L., Xie Z., Montal M.O., Matsuyama S., Montal M., and Reed J.C. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 94 10 (1997) 5113-5118
82. Losonczi J.A., Olejniczak E.T., Betz S.F., Harlan J.E., Mack J., and Fesik S.W. NMR studies of the anti-apoptotic protein Bcl-xL in micelles. Biochemistry 39 36 (2000) 11024-11033
83. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., Murray T., et al. Cancer statistics. CA Cancer J Clin 58 2 (2008) 71-96
84. Albreht T., McKee M., Alexe D.M., Coleman M.P., and Martin-Moreno J.M. Making progress against cancer in Europe in 2008. Eur J Cancer PMID (2008) 18353629